Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard Dose vs Myeloablative Therapy in Multiple Myeloma
NCT00002548Phase 3Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Jan 1994
- Primary completion
- Oct 2003
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of melphalan, interferon alfa in multiple myeloma (MM), sponsored by SWOG Cancer Research Network. Started Jan 1994; status: completed.
02
Drugs
melphalaninterferon alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00002548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002548.